PubMed Health⌕ Search

Biomedical subjects

P Biggio

Publications and source records attributed to P Biggio.

At least 37 records · Page 2Linked to original sources
PubMed1994

Abnormalities of blood coagulation and fibrinolysis in psoriasis.

Contrasting data have been reported about cardiovascular diseases in psoriatic patients. The aim of this study was therefore to evaluate blood coagulation and fibrinolysis in psoriatic patients. For this purpose, in a first group of 48 patients, we measured blood coagulation and fibrinolysis inhibitors [antithrombin III (AT), protein C (PC) and alpha 2-antiplasmin (AP)], the products of thrombin and plasmin activity [fibrinopeptide A (FpA) and B beta(15-42) (B beta)], plasminogen (PLG) and fibrinogen (FBG). When all patients were considered we found a significant increase in B beta and FpA levels, while PC, PLG and AP values were significantly decreased when compared to controls. FBG and AT were not different from the controls. In order to understand whether the observed abnormalities of blood coagulation and fibrinolysis were related only to psoriasis we divided all the patients into two groups: (1) patients with cardiovascular disease or other risk factors (n = 28) and (2) patients affected only by psoriasis (n = 20). Since no difference was observed between groups 1 and 2, we conclude that these findings are related to psoriasis. Subsequently we considered a different group of psoriatic patients. In these patients we measured FpA and two new thrombin activation indicators, such as prothrombin fragment 1 + 2 and thrombin-antithrombin complex (TAT). In addition we evaluated the levels of D-dimer, the product of the dissolution of cross-linking fibrin by plasmin. In this second group FpA, prothrombin fragment 1 + 2 and D-dimer were significantly higher than controls. Only TAT was not statistically different from those of the controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Antithrombin III↗
PubMed1990

Leishmaniasis in Sardinia. IV. Epidemiological appraisal of cutaneous leishmaniasis and biochemical characterization of isolates.

Cutaneous leishmaniasis (CL) is endemic in Sardinia where 250 cases were reported from 1922 to 1988. The province of Sassari, in the north of the island, shows the highest number of cases. The vertical distribution of localities where cases had occurred is analysed and the age distribution of cases is given. Isolation of parasites was attempted in 12 cases, but successful growth of Leishmania was obtained from three cultures only. The stocks belonged to two different zymodemes of L. infantum: zymodeme Montpellier (ZMON) 24 and ZMON 24 MPI variant. The distribution of dermotropic L. infantum zymodemes in the Mediterranean area is discussed and the presence of a possible parasite reservoir is suggested.

Age Factors↗
PubMed1989

[Sweet's syndrome].

The authors describe a clinical case of Sweet's syndrome in a 41-year-old man. From the clinical-instrumental tests carried out a paraneoplastic syndrome is excluded.

Adult↗
PubMed1988

Double-blind study with fenticonazole or bifonazole lotions in pityriasis versicolor.

The efficacy of fenticonazole 2% lotion was studied in patients suffering from pityriasis versicolor in a double-blind comparison with bifonazole 1% lotion, both applied once daily for three weeks. Forty-six patients were recruited and randomly allocated to one or other treatment group. Clinical and mycological examinations, performed at baseline and at weekly intervals, have shown an excellent response to both treatments. Two cases of mild transient desquamation were reported in the fenticonazole group. Fenticonazole 2% lotion appears active in the treatment of pityriasis versicolor and its efficacy is comparable to that of bifonazole.

Adolescent↗
PubMed1987

Clinical experience with fenticonazole 2% formulation in the treatment of dermatomycoses and pityriasis versicolor.

Clinical efficacy of fenticonazole 2% cream has been tested on 30 patients with dermatomycoses and the 2% nebulized lotion on 10 patients with pityriasis versicolor. Treatment consisted of two topical applications of the drug for up to 5 weeks and clinical improvement and mycology were assessed at one-week intervals. Thirty-six patients (90%) were cured at the end of the 5-week period; 26 were cured from dermatomycoses and 10 from pityriasis versicolor. No recurrency/reinfection nor side-effects were encountered. The success attained by fenticonazole treatment indicates that it is a first choice drug in the therapy of superficial dermatomycoses.

Administration, Topical↗
PubMed1986

Ketoconazole: therapeutic results obtained in the district of Cagliari.

The therapeutic results of ketoconazole treatment in 61 patients affected by mycoses at various locations are reported. The mycotic conditions in these patients were: pityriasis versicolor (26), tinea cruris (14), tinea corporis (8), tinea pedis (6), kerion celsi (6) and monilial granuloma (1). Clinical and mycological cure was obtained in 56 cases (91.8%) over a mean treatment period from a minimum of 29 days (pityriasis versicolor) to a maximum of 39 days (tinea pedis) and 150 days (monilial granuloma), with a mean daily dosage of 200 mg in adults and 100 mg in children. The authors stress the high level of tolerability of the drug and its high therapeutic activity. They indicate the conditions for its use in superficial epidermomycoses and kerion celsi and note its unparalleled effect in chronic mucocutaneous candidosis.

Adolescent↗
PubMed1983

[Psoriatic arthritis: considerations on recent studies: serum beta 2 microglobulin and circulating T-gamma lymphocytes].

The results of two recent studies of our group have been reported. They regard two immunological parameters of psoriatic arthritis: the proportions of T gamma lymphocytes in peripheral blood and the beta 2 microglobulin in the serum. The data obtained in psoriatic arthritis patients have been compared to those found in normal controls and in rheumatoid arthritis patients. T gamma mean values in psoriatic arthritis were significantly lower than those present in healthy subjects and in rheumatoid patients. These last patients showed beta 2 microglobulin mean values significantly higher than those observed in normal controls and in psoriatic arthritis patients. Conversely, the mean of beta 2 microglobulin levels in psoriatic arthritis has been found to be similar to that observed in normal controls, but a superimposition in the range of individual values of these two groups with the concentrations determined in rheumatoid subjects has been found. These results seem to be of interest in relation to the immunopathogenetic mechanism of psoriatic arthritis, but are of little help in the clinical differentiation of the two rheumatological affections considered.

Arthritis↗